ABBV Jan 2025 230.000 call
| Previous close | 0.9500 |
| Open | 1.1000 |
| Bid | 0.7600 |
| Ask | 1.0300 |
| Strike | 230.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.9500 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 828 |
PR NewswireAbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE®) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior treatment regimens. Patients with
Investor's Business Daily2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.
Simply Wall St.AbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth Potential
AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and strategic acquisitions to bolster its pipeline. However, challenges such as declining profit margins and competitive pressures persist. In the discussion that follows, we will explore AbbVie's core strengths, critical weaknesses, growth opportunities, and key threats to provide a comprehensive overview of the company's current business situation.
